Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-01 1:02 pm Purchase | 2026-03-26 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Logos Global Management LP | 1,285,000 5.600% | 1,285,000 (New Position) | Filing History |
| 2026-03-06 10:05 am Purchase | 2026-02-27 | 13G | AVALO THERAPEUTICS INC PAR AVTX | FMR LLC | 2,125,819 11.500% | 2,125,819 (New Position) | Filing History |
| 2026-02-24 4:48 pm Purchase | 2026-02-17 | 13G | AVALO THERAPEUTICS INC PAR AVTX | MILLENNIUM MANAGEMENT LLC | 934,429 5.000% | 47,155 (+5.31%) | Filing History |
| 2026-02-17 6:13 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | ORBIMED ADVISORS LLC | 1,187,300 6.400% | 220,300 (+22.78%) | Filing History |
| 2026-02-17 5:00 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 881,533 4.900% | 48,200 (+5.78%) | Filing History |
| 2026-02-17 4:33 pm Sale | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management L.P. | 627,502 3.500% | -426,481 (-40.46%) | Filing History |
| 2026-02-17 4:21 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | RA CAPITAL MANAGEMENT LLC | 1,939,065 9.900% | 552,898 (+39.89%) | Filing History |
| 2026-02-17 4:11 pm Sale | 2026-02-10 | 13G | AVALO THERAPEUTICS INC PAR AVTX | MILLENNIUM MANAGEMENT LLC | 887,274 4.800% | -19,488 (-2.15%) | Filing History |
| 2026-02-17 4:07 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BIOTECHNOLOGY VALUE FUND L P | 1,904,257 9.990% | 446,106 (+30.59%) | Filing History |
| 2026-02-17 06:57 am Sale | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BALYASNY ASSET MANAGEMENT LLC | 439,312 2.420% | -378,124 (-46.26%) | Filing History |
| 2026-02-10 4:07 pm Purchase | 2026-02-03 | 13G | AVALO THERAPEUTICS INC PAR AVTX | MILLENNIUM MANAGEMENT LLC | 906,762 4.900% | 964 (+0.11%) | Filing History |
| 2026-02-10 11:36 am Sale | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | SilverArc Capital Management, LLC | 524,436 2.830% | -196,486 (-27.25%) | Filing History |
| 2026-02-03 5:19 pm Purchase | 2026-01-28 | 13G | AVALO THERAPEUTICS INC PAR AVTX | MILLENNIUM MANAGEMENT LLC | 905,798 4.900% | 905,798 (New Position) | Filing History |
| 2026-01-30 1:25 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | VANGUARD GROUP INC | 804,084 4.430% | 111,447 (+16.09%) | Filing History |
| 2026-01-29 7:56 pm Purchase | 2026-01-22 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors LLC | 1,051,054 5.700% | 44,837 (+4.46%) | Filing History |
| 2025-11-14 6:26 pm Sale | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Ikarian Capital, LLC | 711,967 3.800% | -479,990 (-40.27%) | Filing History |
| 2025-11-14 4:54 pm Purchase | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Nantahala Capital Management LLC | 1,235,000 9.390% | 335,000 (+37.22%) | Filing History |
| 2025-11-14 4:12 pm Purchase | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | RA CAPITAL MANAGEMENT LLC | 1,386,167 9.900% | 291,760 (+26.66%) | Filing History |
| 2025-11-14 4:11 pm Purchase | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management L.P. | 1,053,983 8.000% | 465,351 (+79.06%) | Filing History |
| 2025-11-14 4:00 pm Purchase | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BIOTECHNOLOGY VALUE FUND L P | 1,458,151 9.990% | 419,609 (+40.40%) | Filing History |